Stocks To Buy Today: SBI Life, Grasim, Marico Among Others

For Monday's stock market trading session, SBI Life Insurance stands out with the highest potential upside of 18.75%, as recommended by Kunal Rambhia, founder of The Street. Alongside this, Ajit Mishra, SVP-Research at Religare Broking, has recommended Grasim and Marico.

Here are the detailed recommendations.

Rambhia recommends buying SBI Life Insurance Co. with a target price of Rs 1,900 per share. The current price is Rs 1,691, and the stop loss price is set at Rs 1,600.

Out of 36 analysts tracking the company, 33 maintain a 'buy' rating and three maintain a 'hold' rating on the stock, with a potential upside of 15.1%.

Ajit Mishra, SVP-Research at Religare Broking, suggests buying Grasim Industries Ltd. The target price is Rs 2,950, while the current price is Rs 2,735. The stop loss price is set at Rs 2,640.

Out of nine analysts tracking the company, six maintain a 'buy' rating, two maintain a 'hold' rating and one maintains a 'sell' on the stock, with a potential upside of 7.1%.

Mishra also recommends buying Marico Ltd., with a target price of Rs 740. The current price is Rs 710.4, and the stop loss price is Rs 695.

Out of 42 analysts tracking the company, 31 maintain a 'buy' rating, eight recommend a 'hold' rating and three suggest a 'sell' on the stock with a potential upside of 37.9%.

Rambhia advises buying Alembic Pharmaceuticals, setting the target price at Rs 915. The current price is Rs 875, and the stop loss price is also Rs 860.

Out of the 13 analysts tracking the company, six maintain a 'buy' rating, five recommend a 'hold' rating and two suggest a 'sell' on the stock, with a potential upside of 11.9%.

Another recommendation from Kunal Rambhia is Dr. Lal PathLabs, with a target price of Rs 3,100. The current price is Rs 2,827, and the stop loss price is Rs 2,875.

Out of 28 analysts tracking the company, 18 maintain a 'buy' rating, two maintain a 'hold' rating and eight suggest a 'sell' on the stock, with a potential upside of 11%.